摘要
目的研究β-地中海贫血患者长期红细胞输注中应用RhCcEe抗原配合性输血策略的效果。方法选取2018年5月至2019年8月郑州大学附属儿童医院收治的86例β-地中海贫血患者作为研究对象,采用系统随机化法均分为研究组(ABO、RhC、c、D、E、e抗原相合性或相容性输血)和对照组(ABO、RhD相合性输血)。观察两组输血12周后的临床疗效,比较两组输血前及输血12周后的血液学指标[血红蛋白(Hb)、血细胞比容(HCT)]、心脏功能[脑钠肽(BNP)、心肌肌钙蛋白Ⅰ(cTnⅠ)],观察两组不良反应发生情况及不规则抗体产生情况。结果输血12周后,两组治疗总有效率比较,差异无统计学意义(P>0.05)。输血12周后,研究组Hb、HCT水平均较输血前显著上升(P<0.05),输血前及输血12周后,两组Hb、HCT水平比较,差异无统计学意义(P>0.05)。输血12周后,两组BNP、cTnⅠ水平均较输血前显著下降,研究组明显低于对照组(P<0.05)。研究组不良反应发生率明显低于对照组(P<0.05)。两组不规则抗体阳性率比较,差异无统计学意义(P>0.05)。结论RhCcEe抗原配合性输血策略在β-地中海贫血患者长期红细胞输注中应用效果良好,能够有效地减少患者输血不良反应,改善心脏功能。
[Objective]To study the application effects of RhCcEe antigen-compatible blood transfusion strategy in long-term erythrocyte transfusion in patients withβ-thalassemia.[Methods]Eighty-six patients withβ-thalassemia admitted to our hospital from May 2018 to August 2019 were selected as the research subjects,and they were divided into study group(ABO,RhC,c,D,E,e antigen-compatible blood transfusion)and control group(ABO,RhD-compatible blood transfusion)by systematic randomization.The clinical efficacy was observed in the two groups after 12 weeks of blood transfusion,and the hematological indicators[hemoglobin(Hb),hematocrit(HCT)]and cardiac function[brain natriuretic peptide(BNP),cardiac troponin I(cTnI)]were observed in the two groups before blood transfusion and after 12 weeks of blood transfusion,and the occurrence of adverse reactions and the production of irregular antibodies were observed in the two groups.[Results]After 12 weeks of blood transfusion,there was no significant difference in the total effective rate of treatment between the two groups(P>0.05).After 12 weeks of blood transfusion,the levels of Hb and HCT in study group were significantly higher than those before blood transfusion(P<0.05).Before blood transfusion and after 12 weeks of blood transfusion,there were no statistically significant differences in the levels of Hb and HCT between the two groups(P>0.05).After 12 weeks of blood transfusion,the levels of BNP and cTnI in the two groups were significantly lower than those before blood transfusion,and the levels in study group were significantly lower than those in control group (P<0.05). The incidence rate of adverse reactions in study group was significantly lower than that in control group (P<0.05).There were no significant differences in the positive rates of irregular antibodies between the two groups (P>0.05). [Conclusion]RhCcEeantigen-compatible blood transfusion strategy has a good application effect in the long-term erythrocyte transfusion in patients withβ-thalassemia, and it can effectively reduce the adverse reactions of blood transfusion and improve cardiac function.
作者
杨政道
赵鼎
田冬冬
YANG Zhengdao;ZHAO Ding;TIAN Dongdong(Children's Hospital Affiliated to Zhengzhou University(Henan Children's Hospital,Zhengzhou Children's Hospital),Zhengzhou,Henan 450000,China)
出处
《中国医学工程》
2021年第5期36-39,共4页
China Medical Engineering
关键词
Β-地中海贫血
红细胞输注
RH血型系统
配合性输血
β-thalassemia
erythrocyte transfusion
Rh blood-group system
compatible blood transfusion
